UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1723, 2025

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	001-39724	85-1710962
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

419 Davis Drive, Suite 100, Morrisville, North Carolina	27560
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock	LQDA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 58.0701 ~~Submission~~Other ~~of Matters to a Vote of Security Holders~~Events.

On June 1723, 2025, Liquidia Corporation, a Delaware corporation (the “Company”), ~~held~~issued ~~its~~a ~~annual~~press ~~meeting~~release ofannouncing ~~stockholders (~~the ~~“Annual~~receipt ~~Meeting”)~~of an additional $50.0 Atmillion under the ~~Annual Meeting,~~Sixth Amendment to the ~~following~~Revenue ~~matters~~Interest ~~were~~Financing ~~submitted~~Agreement, todated aMarch ~~vote~~17, of2025 ~~stockholders:~~(the “HCR Agreement”), with HealthCare Royalty Partners IV, L.P. (“HCR”)

1Under the HCR Agreement, an additional $50.0 ~~The~~million of ~~election~~funding is available to the Company after the first commercial sale of ~~three~~YUTREPIA following receipt of final FDA approval for the treatment of pulmonary arterial hypertension (3“PAH”) ~~Class~~and Ipulmonary ~~directors~~hypertension associated with interstitial lung disease (“PH-ILD”), toso ~~serve~~long ~~until~~as no injunction has been issued prohibiting Liquidia from commercializing YUTREPIA™ (treprostinil) for either or both of PAH and PH-ILD (“Funding Condition”). The Funding Condition was satisfied when (i) on May 30, 2025, the ~~Company~~U.S. District Court for the Middle District of North Carolina denied United Therapeutics Corporation’s ~~2028~~request ~~Annual~~for ~~Meeting~~a ofpreliminary ~~Stockholders~~injunction and a temporary restraining order in its complaint filed against the Company and (ii) on June 2, or2025, ~~until~~the ~~their~~Company ~~respective~~made ~~successors~~its ~~shall~~first ~~have~~commercial ~~been~~shipment of ~~duly~~YUTREPIA ~~elected~~inhalation powder. An additional funding of $25.0 million remains available under the HCR Agreement upon mutual agreement of HCR and ~~qualified;~~the Company if the Company achieves aggregate net sales of YUTREPIA in excess of $100 million at any time on or prior to June 30, 2026.

2.A ~~The~~copy ~~ratification~~ of the ~~appointment~~press ofrelease ~~PricewaterhouseCoopers LLP~~is filed as ~~the~~Exhibit 99.1 ~~Company’s~~hereto ~~independent~~and ~~registered~~is ~~public~~incorporated ~~accounting~~by ~~firm~~reference ~~for~~into ~~the~~this ~~year~~Item ~~ending December 31, 2025; and~~8.01.

3. The approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers (the “NEOs”).

At the close of business on April 23, 2025, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 85,448,787 shares of common stock outstanding and entitled to vote at the Annual Meeting. The holders of 67,560,757 shares of common stock were represented virtually or by proxy at the Annual Meeting, constituting a quorum.

At the Annual Meeting, the three Class I directors were elected, the appointment of the Company’s independent registered public accounting firm for the year ending December 31, 2024 was ratified and the compensation of the NEOs was approved by non-binding advisory vote.

Proposal No. 1- Election of Class I Directors

The vote with respect to the election of Class I directors was as follows:

Nominees	For		Withheld		Broker Non- Votes
Stephen Bloch, M.D.		39,609,683		6,598,760		21,352,314
Joanna Horobin, M.B., C.H.B.		45,361,656		846,787		21,352,314
Roger A. Jeffs, Ph.D.		46,091,138		117,305		21,352,314

Proposal No. 2 - Ratification of the Appointment of Independent Registered Public Accounting Firm

The vote with respect to the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025 was as follows:

For				Against				Abstain
	67,519,260				30,220				11,277

Proposal No. 3 – Approval, by Non-Binding Advisory Vote, of the Compensation of the NEOs

The vote with respect to the approval, by non-binding advisory vote, of the compensation of the NEOs was as follows:

For				Against				Abstain				Broker Non-Votes
	44,393,482				1,313,301				501,660				21,352,314

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit
99.1		Press Release of Liquidia Corporation, dated June 23, 2025.
104		Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 18, 2025	Liquidia Corporation
June 23, 2025	Liquidia Corporation
	By:	/s/ Michael Kaseta
		Name: Michael Kaseta
		Title: Chief Financial Officer and Chief Operating Officer

Filing Compare · Liquidia Corp